February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
January 2019 in “Nihon Yakuri Gakkai nenkai yoshishu” Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.
1 citations
,
September 2024 in “African Journal of Urology” Dutasteride is slightly better than finasteride for treating BPH but has fewer sexual side effects.
April 2018 in “The Journal of Urology” Dutasteride use can lead to a stable decline in sexual function that is not affected by age or prostate size.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
April 2013 in “The FASEB Journal” Dutasteride showed some prevention of prostate issues but also had limitations, especially with high-grade tumors.
17 citations
,
June 1996 in “The Journal of Steroid Biochemistry and Molecular Biology” FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
110 citations
,
August 2015 in “Neuropsychopharmacology” High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.
6 citations
,
October 2021 in “Brain Sciences” Dutasteride may help reduce brain inflammation and improve cognition.
November 2005 in “The Journal of Urology” Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.
Flutamide helps with prostate cancer and some skin conditions but can harm the liver.
9 citations
,
March 1991 in “Endocrinology” Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.
4 citations
,
September 2024 in “BMC Cancer” Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.
August 2002 in “Inpharma Weekly”
9 citations
,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
6 citations
,
January 1996 in “Endocrine-related Cancer” Combining flutamide and finasteride can reduce prostate weight and tumor growth, potentially benefiting treatments needing optimal DHT inhibition.
Dutasteride reduces prostate cancer risk by 23% in high-risk men.
September 2024 in “Dermatology” Dutasteride works better than finasteride for hair loss and has mild, reversible side effects.
August 2025 in “Fabad Journal of Pharmaceutical Sciences” Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.
29 citations
,
July 2009 in “BJU international” Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
14 citations
,
December 1998 in “The Journal of Clinical Endocrinology and Metabolism” MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.
97 citations
,
May 2004 in “British Journal of Urology” Dual therapy with specific medications can help manage male urinary symptoms and reduce side effects.
April 2015 in “Reactions Weekly” May 2013 in “Reactions Weekly” December 2012 in “Reactions Weekly” January 2009 in “Reactions Weekly” 4 citations
,
November 2021 in “Journal of The American Academy of Dermatology” Bicalutamide may reduce unwanted hair growth caused by minoxidil in women with hair loss.
August 2011 in “Reactions Weekly” June 2014 in “Reactions Weekly” January 2014 in “Reactions Weekly”